News Modus Therapeutics Holding AB

Equities

MODTX

SE0015987904

Market Closed - Nasdaq Stockholm Other stock markets 10:55:15 2024-04-25 am EDT			5-day change	1st Jan Change
0.996 ^SEK	-3.30%		-2.83%	-42.59%

Feb. 21	Modus Therapeutics Holding AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
2023	Modus Therapeutics to Launch SEK40 Million Rights Offering, Issue Shares to Offset SEK20 Million Loan	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Notice to Annual General Meeting in Modus Therapeutics Holding	Apr. 17	AQ
Modus Therapeutics Holding AB (publ) publishes annual report for the financial year 2023	Apr. 11	AQ
Modus Therapeutics publishes year-end report for 2023	Feb. 21	AQ
Modus Therapeutics Holding AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 21	CI
The Rights Issue is Registered and Trading in Paid Subscribed Shares Ceases	Dec. 13	AQ
Modus Therapeutics presented data on sevuparin demonstrating its potential to treat anemia in chronic kidney disease at the annual American Society of Hematology (ASH)	Dec. 11	AQ
Modus Therapeutics Holding AB Announces Final Outcome in Rights Issue	Dec. 05	AQ
Modus Therapeutics Holding AB Publishes Prospectus in Connection with the Upcoming Rights Issue	Nov. 14	AQ
Modus Therapeutics to Launch SEK40 Million Rights Offering, Issue Shares to Offset SEK20 Million Loan	Nov. 08	MT
Modus Therapeutics Holding AB Conducts a Rights Issue of 40.3 MSEK and an Offset Issue of 20.3 MSEK	Nov. 08	AQ
Modus Therapeutics publishes interim report for the third quarter 2023	Nov. 08	AQ
Modus Therapeutics Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Modus Therapeutics to present at the 2023 American Society of Hematology Meeting and Exposition (ASH): New data on sevuparin and its potential to treat chronic kidney disease anemia and reduce kidney injury.	Nov. 02	AQ
Modus Therapeutics presents final data from its Phase 1b LPS-provocation study with sevuparin at the annual ISICIP symposium in Barcelona	23-10-05	AQ
Modus Therapeutics publishes interim report for the second quarter 2023	23-08-23	AQ
Modus Therapeutics Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-23	CI
Modus Therapeutics presented new data on sevuparin demonstrating its potential to treat anemia related to chronic diseases at the annual European Hematology Association Congress	23-06-12	AQ
Modus Therapeutics to present at the annual European Hematology Association Congress, new data on sevuparin and its potential to treat anemia of chronic disease by suppression of hepcidin	23-05-12	AQ
Annual General Meeting in Modus Therapeutics Holding AB (publ)	23-05-11	AQ
Modus Therapeutics publishes interim report for the first quarter 2023	23-05-09	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Modus Therapeutics Holding AB

Equities

MODTX

SE0015987904

Summary

Filters